Scholarlink

<p>Promising study results from the past year indicate new therapeutic approaches in both the pharmacological and technological fields for type&#xa0;1 diabetes (T1D). In the area of immunological therapy options, the use of antibodies is being explored. In addition to teplizumab, ustekinumab showed an improvement in beta cell function in a&#xa0;phase&#xa0;2&#xa0;study. Furthermore, an islet cell transplant in a&#xa0;patient with T1D resulted in impressive remission of the disease, even leading to insulin independence. Moreover, the use of novel weekly insulins in T1D has continued to be investigated, with initial study results documenting an increased hypoglycemia rate in patients with T1D when using these insulins. Inhaled insulin was also explored as a&#xa0;new therapeutic modality but did not show an improvement in postprandial hyperglycemia rates in automated insulin delivery (AID) users compared to regular subcutaneous insulin injection. Additionally, the use of AID systems continues to show great potential in optimizing glycemic control in T1D. Especially in older patients, they can help reduce hypoglycemia and improve quality of life. Complementary pharmacological options such as glucagon-like peptide‑1 receptor agonists (GLP-1RAs) and sodium–glucose cotransporter 2 inhibitors (SGLT2) are also being intensively researched to reduce diabetes-related complications in people with T1D in the future. The use of both drug classes has increased in recent years in T1D and shows positive effects, particularly in terms of weight control and cardiovascular as well as renal outcomes. However, longer-term studies are necessary to evaluate the safety and effectiveness of medications that have not yet been approved for T1D.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Typ 1 Diabetes mellitus

  • 期刊论文

  • 发表日期：

    2025年6月10日

查看全文
  • Marleen Würfel,
  • Thomas Ebert

摘要

Promising study results from the past year indicate new therapeutic approaches in both the pharmacological and technological fields for type 1 diabetes (T1D). In the area of immunological therapy options, the use of antibodies is being explored. In addition to teplizumab, ustekinumab showed an improvement in beta cell function in a phase 2 study. Furthermore, an islet cell transplant in a patient with T1D resulted in impressive remission of the disease, even leading to insulin independence. Moreover, the use of novel weekly insulins in T1D has continued to be investigated, with initial study results documenting an increased hypoglycemia rate in patients with T1D when using these insulins. Inhaled insulin was also explored as a new therapeutic modality but did not show an improvement in postprandial hyperglycemia rates in automated insulin delivery (AID) users compared to regular subcutaneous insulin injection. Additionally, the use of AID systems continues to show great potential in optimizing glycemic control in T1D. Especially in older patients, they can help reduce hypoglycemia and improve quality of life. Complementary pharmacological options such as glucagon-like peptide‑1 receptor agonists (GLP-1RAs) and sodium–glucose cotransporter 2 inhibitors (SGLT2) are also being intensively researched to reduce diabetes-related complications in people with T1D in the future. The use of both drug classes has increased in recent years in T1D and shows positive effects, particularly in terms of weight control and cardiovascular as well as renal outcomes. However, longer-term studies are necessary to evaluate the safety and effectiveness of medications that have not yet been approved for T1D.